Intellia Therapeutics Inc (NASDAQ:NTLA) price on Thursday, May 22, rose 2.83% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $9.46.
A look at the stock’s price movement, the close in the last trading session was $9.20. Turning to its 52-week performance, $28.18 and $5.90 were the 52-week high and 52-week low respectively. Overall, NTLA moved 16.93% over the past month.
Intellia Therapeutics Inc’s market cap currently stands at around $979.90 million, with investors looking forward to this quarter’s earnings report slated for in June.
The average forecast suggests up to a 77.47% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 56.14M, representing a -3.00% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that NTLA is a Hold. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 50% Sell category.
13 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 13 recommend NTLA as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
NTLA’s current price about 11.67% and 16.36% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 59.58, while 7-day volatility ratio is 5.39% and 6.12% in the 30-day chart. Further, Intellia Therapeutics Inc (NTLA) has a beta value of 2.26, and an average true range (ATR) of 0.68. Analysts have given the company’s stock an average 52-week price target of $17.5, forecast between a low of $9 and high of $26. Looking at the price targets, the low is 4.86% off current price level while to achieve the yearly target high, price needs to move -174.84%. Nonetheless, investors will most likely welcome a -84.99% jump to $17.5 which is the analysts’ median price.
If we refocus on Intellia Therapeutics Inc (NASDAQ:NTLA), historical trading data shows that trading volumes averaged 3.54 million over the past 3 months. The company’s latest data on shares outstanding shows there are 103.54 million shares.
The 5.90% of Intellia Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 91.97% of the company’s shares. Current price change has pushed the stock -18.87% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the NTLA stock continues to rise going into the next quarter.
